Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLARIS-1: Olverembatinib vs investigator's choice of TKI with chemotherapy in newly diagnosed Ph+ ALL
jRCT2031260426Phase 3Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Aug 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of olverembatinib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Ascentage Pharma. Primary endpoint: MRD-negative complete remission rate. Started Aug 2026; status: recruiting.
02
Drugs
olverembatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCT2031260426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260426.